European Journal of Paediatric Neurology

Stoke Therapeutics Presents Data Related to the Ongoing Clinical Development of STK-001 for the Treatment of Dravet Syndrome at the 35th International Epilepsy Congress

Retrieved on: 
Tuesday, September 5, 2023

Four posters from the Company’s work in Dravet syndrome are being presented at the International Epilepsy Congress (IEC) 2023, September 2-6, in Dublin, Ireland.

Key Points: 
  • Four posters from the Company’s work in Dravet syndrome are being presented at the International Epilepsy Congress (IEC) 2023, September 2-6, in Dublin, Ireland.
  • Dravet syndrome is a severe and progressive genetic epilepsy characterized by frequent, prolonged and refractory seizures beginning within the first year of life.
  • The disease is classified as a developmental and epileptic encephalopathy due to the developmental delays and cognitive impairment associated with the disease.
  • All presentations are available for download on the Stoke Therapeutics website under the Investors & News tab.

Stoke Therapeutics Presents Data from a Combined Interim Analysis of the Phase 1/2a MONARCH and ADMIRAL Studies of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2022 Annual Meeting

Retrieved on: 
Friday, December 2, 2022

A total of seven posters will be presented at the American Epilepsy Society (AES) 2022 Annual Meeting, December 2-6.

Key Points: 
  • A total of seven posters will be presented at the American Epilepsy Society (AES) 2022 Annual Meeting, December 2-6.
  • Dravet syndrome is a severe and progressive genetic epilepsy characterized by frequent, prolonged and refractory seizures beginning within the first year of life.
  • STK-001 represents an entirely new approach to treatment, one that aims to treat the syndrome, not just the seizures.
  • Topline data from a combined interim analysis of the Phase 1/2a MONARCH and ADMIRAL studies showed single and multiple doses of STK-001 up to 45mg were well-tolerated.

Stoke Therapeutics to Present Data from the Company’s Dravet Syndrome Program at the American Epilepsy Society 2022 Annual Meeting

Retrieved on: 
Tuesday, November 29, 2022

The company is advancing STK-001 as potentially the first medicine to treat the underlying cause of Dravet syndrome.

Key Points: 
  • The company is advancing STK-001 as potentially the first medicine to treat the underlying cause of Dravet syndrome.
  • Compared with the general epilepsy population, people living with Dravet syndrome have a higher risk of sudden unexpected death in epilepsy, or SUDEP.
  • STK-001 is an investigational new medicine for the treatment of Dravet syndrome currently being evaluated in ongoing clinical trials.
  • Stokes first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy.

Stoke Therapeutics Announces Presentations from the Company’s Dravet Syndrome Program at the American Epilepsy Society 2021 Annual Meeting

Retrieved on: 
Friday, November 19, 2021

At Stoke, our goal is to develop the first medicine to target the underlying cause of Dravet syndrome, a severe and progressive genetic epilepsy, said Barry Ticho, M.D., Ph.D., Chief Medical Officer of Stoke Therapeutics.

Key Points: 
  • At Stoke, our goal is to develop the first medicine to target the underlying cause of Dravet syndrome, a severe and progressive genetic epilepsy, said Barry Ticho, M.D., Ph.D., Chief Medical Officer of Stoke Therapeutics.
  • Compared with the general epilepsy population, people living with Dravet syndrome have a higher risk of sudden unexpected death in epilepsy, or SUDEP.
  • STK-001 is an investigational new medicine for the treatment of Dravet syndrome currently being evaluated in ongoing clinical trials.
  • The Companys first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy.